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Introduction
Human endogenous retroviruses (HERV) represent approximately 8% of the human genome and result from integration of exogenous retroviruses that infected the germline of their hosts during primate evolution (Belshaw et al., 2004) . HERV belong to the superfamily of repeated and transposable elements and retain properties of mobile genetic elements although most contemporary HERV copies are inactivated by mutations, deletions, or silenced by epigenetic modifications (Belshaw et al., 2005; Romanish et al., 2010) . The first description of retrovirus-like particles with reverse transcriptase activity in leptomeningeal and macrophage cell cultures from multiple sclerosis (MS) patients suggested a viral origin of the disease (Perron et al., 1991) . However, further molecular characterisation of this Multiple Sclerosis-associated RetroVirus (MSRV) revealed that it was not a classical infectious exogenous retrovirus but the forming member of the W family of HERV (HERV-W) (Blond et al., 1999; Komurian-Pradel et al., 1999; Perron et al., 1997) . Though HERV-W elements are usually truncated or lack open reading frames (orf), several chromosomal copies retain potential orf for viral proteins (Voisset et al., 2000) . Interestingly, certain exogenous viral agents can trigger the reactivation of MSRV copies, particularly Herpesviridae which have been often associated with MS epidemiology without demonstrating a causative role in the disease. Thus, reactivation of silent MSRV, which exhibits pathogenic properties, by such environmental infectious agents may be the missing link between environment and MS onset (Perron and Lang, 2010) . Following the initial isolation of MSRV particles from cerebral tissues of MS patients, numerous independent studies in humans performed by two research groups have associated MS with an elevated MSRV expression, in particular its MSRV envelope protein (MSRV-Env) in serum or its corresponding RNA in human peripheral blood mononuclear cells (hPBMC) Mameli et al., 2007; Perron et al., 2012) . Furthermore, MSRV-Env protein was detected on the cell surface of infiltrated macrophages and activated microglia in MS brain lesions, but not in normal appearing white matter or control brains (Kremer et al., 2013; Perron et al., 2012) .
MS is a devastating chronic inflammatory demyelinating disease of the central nervous system (CNS). Although its aetiology is not elucidated yet, MS probably has an autoimmune component. The presence of infiltrating T-cells, monocytes and macrophages in the brain lesions of MS patients suggests that innate immune system plays a pivotal role in the mediation of cerebral damages (Weiner, 2009) . Several studies show that MSRV virions or its envelope protein elicit immunopathogenic and pro-inflammatory responses on human T lymphocytes and hPBMC (Perron et al., 2001; Rolland et al., 2006) . More recently, Kremer et al. (2013 Kremer et al. ( , 2014 showed that MSRV-Env induces the expression of pro-inflammatory cytokines and inducible NO synthase by oligodendrocyte precursors cells (OPC) in culture. Furthermore, the authors report that MSRV-Env decreases the differentiation capacity of rat OPC to mature myelinating cells. Some of these MSRV-Env effects were attributed to toll-like receptor 4 (TLR4) activation though not characterised (Kremer et al., 2013; Rolland et al., 2006) . TLR signalling plays a crucial role in innate immunity through initiation of host defence responses to microbial infection (Hanke and Kielian, 2011 ) and these observations suggest that MSRV-Env pathogenic properties may be involved in MS.
As the aetiology of MS is unknown, there are no causal treatments of the disease. Though major progresses have been recently achieved with new oral treatments, existing therapies only alter the course of MS and once the disease develops it is lifelong. Furthermore available treatments, which are approved for the relapse-remitting form of MS, are in general strong immunomodulators associated with substantial safety risks, but they have shown only marginal or no effect in the progressive forms of the disease. There is a critical medical need for innovative and safer MS treatments, in particular dedicated to the progressive forms of the disease where remyelination impairments prevail (Curtin and Hartung, 2014) . Thus, as MSRV-Env expression is associated with MS, exhibits pro-inflammatory properties and potentially impairs brain remyelination, a humanised monoclonal antibody targeting MSRVEnv, named GNbAC1, has been developed as an innovative therapeutic approach for MS .
We performed the first pharmacological characterisation of MSRVEnv interaction with recombinant human TLR4 (hTLR4) and demonstrated that MSRV-Env is an endogenous and highly potent full agonist of hTLR4. Then, we performed the characterisation of MSRV-Env interaction with native hTLR4 expressed by hPBMC and human OPC (hOPC). This study confirms previous reports suggesting MSRV-Env pro-inflammatory properties in vitro and we show that this MSRVEnv feature is mirrored in vivo. Furthermore, we show that MSRV-Env impairs hOPC differentiation to mature myelinating oligodendrocytes through hTLR4 activation. GNbAC1 antagonizes all the pathogenic effects of MSRV-Env investigated, supporting the fact that GNbAC1 may provide a new and targeted therapeutic approach to the treatment of MS.
Materials and methods

Recombinant proteins and chemicals
Three different recombinant MSRV-Env proteins were used in this study. The full length MSRV-Env-T protein was produced from plasmid pV14 encompassing the complete orf of MSRV-Env cloned from MSRV virion RNA (58 kDa, 542 aminoacids, GenBank no. AF331500.1). MSRV-Env-SU is a 33 kDa and 293 aminoacids fraction of the extracellular domain of MSRV-Env-T. Both proteins were produced in Escherichia coli. MSRV-Env-SUG is the glycosylated form of MSRV-Env-SU and was produced in HEK 293 human cell line. Recombinant MSRV-Env proteins were produced by Protein'Expert (Grenoble, France) as previously described (Perron et al., 2013; Rolland et al., 2005 Rolland et al., , 2006 .
GNbAC1 is a humanized monoclonal antibody of the IgG4/kappa class that selectively binds with high affinity to the extracellular domain of MSRV-Env protein (Curtin et al., 2012 . GNbAC1 vehicle (20 mM histidine, 5% (w/v) sucrose, 0.01% (w/v) polysorbate 20, pH 6.0) was systematically used as a negative control in all experiments. Natalizumab (Biogen-Dompé, Zug, Switzerland), another humanized IgG4 antibody specific for the cell adhesion molecule α4-integrin, was systematically used as a GNbAC1 isotype control in this study but not in hPBMC experiments since it exerts a direct effect in this model. LPS is the prototypical TLR4 agonist and was used as a positive control in experiments performed with recombinant hTLR4. CD14 acts as a co-receptor of TLR4 and anti-human CD14 or TLR4 antibodies were used as selective blockers of the hTLR4/CD14 receptor complex. LPS-RS is a characterized competitive LPS antagonist extracted from Rhodobacter sphaeroides (Stevens et al., 2013) , and Cli-095 is a selective intracellular suppressor of TLR4 signalling (Kawamoto et al., 2008; Matsunaga et al., 2011) . LPS-EK Ultrapure, anti-human CD14 IgA, antihuman TLR4 IgG and corresponding isotype controls antibodies, LPS-RS, and Cli-095 were purchased from Invivogen (Toulouse, France). Polymyxin B (PMB) inhibits LPS liaison to LPS binding protein (LBP), was used as a selective LPS inhibitor and was purchased from Sigma (Buch, Switzerland). Mouse anti-CNPase (2′,3′-Cyclic nucleotide-3′-phosphohydrolase) and anti-MBP (Myelin Basic Protein) antibodies were purchased from Covance (Paris, France).
HEK-blue™-TLR4 cells culture and TLR4 signalling assays
HEK-Blue™-hTLR4 and HEK-Blue™-mTLR4 cells were obtained by co-transfection of the human or murine TLR4, MD-2 and CD14 coreceptor genes, and an inducible SEAP (secreted embryonic alkaline phosphatase) reporter gene into HEK293 cells. The SEAP reporter gene is placed under the control of an Il-12 p40 minimal promoter fused to five NF-κB and AP-1 binding sites. Stimulation with a TLR4 agonist activates NF-κB and AP-1 which induce the production of SEAP assessed by a colorimetric assay. HEK-Blue™ Null2 is the parental negative control cell line of HEK-Blue™-hTLR4 and HEK-Blue™-mTLR4 cells. HEK-Blue™-hTLR4, HEK-Blue™ Null2 and HEK-Blue™-mTLR4 (Invivogen, Toulouse, France) culture was performed according to supplier's recommendations. In first experiments, HEK-Blue™-hTLR4 cells were classically stimulated by agonists and/or antagonists for 24 h in the recommended culture medium. In subsequent pharmacological investigations, the manufacturer's protocol was adapted to a 30 min stimulation with agonists and/or antagonists followed by a 15.5 h incubation before revelation, in Pro293A-CDM (Lonza, Basel, Switzerland), a serum-free culture medium supplemented with 50 U mL −1 penicillin (Life Technologies, Basel, Switzerland), 50 μg mL −1 streptomycin (Life Technologies, Basel, Switzerland) and 100 μg mL − 1 Normocin (Invivogen, Toulouse, France). TLR4 activation was revealed colorimetrically with QUANTI-Blue™ detection assay (Invivogen, Toulouse, France). Optical densities were measured with a Biotek EL800 microplate reader at 650 nm with the KC Junior software (Biotek, Luzern, Switzerland).
Human PBMC cultures and cytokines ELISA
Buffy coats from healthy donors were purchased from the Centre for Blood Transfusion of Geneva (Switzerland). Accordingly, this study was not reviewed by an Institutional Review Board or Ethics Committee as all healthy donors signed a written Informed Consent Form, documented at the Centre for Blood Transfusion of Geneva, allowing the commercial use of their blood and blood components for medical research after definitive anonymization. All individual set of experiments presented here were performed with hPBMC from the same blood donor. hPBMC were isolated by Ficoll separation from buffy coats, aliquoted and frozen at − 80°C. For MSRVEnv-T concentration-response experiments, hPBMC frozen in DMSO 10% in foetal bovine serum (FBS, Biowest, Nuaillé, France) were thawed and directly stimulated for 24 h with MSRV-Env-T in 96-well plates in FBS 10%, penicillin/streptomycin 1%, MEM nonessential amino acids solution 1%, and sodium pyruvate 1 mM in RPMI culture media (Gibco, Life Technologies, Basel, Switzerland). For MSRV-Env-T inhibition experiments, hPBMC frozen in CTL-Cryo™ ABC solution (Cellular Technology Ltd., Bonn, Germany) were thawed and directly stimulated for 24 h with MSRV-Env-T in 96-well plates in serum-free medium (CTL-Test Medium, Cellular Technology Ltd., Bonn, Germany). Then, culture supernatants were collected and frozen at − 20°C before quantification of IL-6 and TNF-α by dedicated Ready-SET-Go ELISA according to manufacturer's instructions (eBioscience, Vienna, Austria).
Cytokines induction in mice
Thirty adult C57BL/6 female mice (9-12 weeks old, Taconic Farms, Germantown, NY) were used in this study, performed by Hooke Laboratories (Lawrence, MA). All procedures were conducted in accordance to, and specifically approved by, the Hooke's Institutional Animal Care and Use Committees (Hooke's IACUC, permit number IC-CytokineProd1312KO2_Amd1), which relies on NIH guidelines, and reported in accordance to the ARRIVE guidelines for reporting animal experiments (Kilkenny et al., 2010) . Blood collection was performed under CO 2 anaesthesia, and all efforts were made to minimize suffering. Mice were housed 5 per cage, in a temperature and humidity-controlled room with a 12 h light/dark cycle and free access to food and water (milliQ purified and UV sterilized). All mice were acclimated for at least 7 days before being assigned to 3 groups in a balanced manner to achieve similar weight at the beginning of the study. MSRV-Env-T (3.3 mg kg
) was administered intravenously along with corresponding GNbAC1 vehicle or together with GNbAC1 (1.6 mg kg − 1 ), at a constant volume of 140 μL per mice (mean weight of 18.3 g per mice in both groups). One mouse per group was rejected because administration failed. The control group (n = 10) was administered by corresponding MSRV-Env-T and GNbAC1 vehicles. Two hours after compounds administration, mice were deeply anesthetised with CO 2 and 0.2 to 0.4 mL of blood per mouse was collected by cardiac puncture before CO 2 euthanasia. Serum was isolated and frozen before subsequent determination of IL-6 and TNF-α concentrations by Cytometric Bead Array analyses according to manufacturer's instructions (Becton-Dickinson, San Jose, CA, USA).
Human OPC culture and immunocytochemistry
Oligodendrocytes precursor cells isolated from human brain tissue and corresponding culture reagents were purchased from ScienCell Research Laboratories (Carlsbad, CA). The complete hOPC culture medium (OPCM) was reconstituted by addition of OPC growth solution and penicillin/streptomycin to the OPCM according to manufacturer's recommendations. After thawing, hOPC were diluted in OPCM and seeded (7000 cells/cm 2 = 10,000 cells per well) into 8-wells labtek culture vessels (Nunc, Roskilde, Denmark) previously coated with poly-L-lysine (0.01%, Sigma, Saint Quentin Fallavier, France). Pharmacological treatments were applied to hOPC directly after cells were seeded. Then, hOPC were incubated at 37°C, 5% CO 2 for 24 h or 72 h before being fixed in a 4% paraformaldehyde in Phosphate Buffer Saline (PBS, Life Technologies, Saint Aubin, France) solution at room temperature for 1 h. OPCM was changed the next day to remove unattached or dead cells in the cultures treated for 72 h. After fixation, hOPC were washed 3 times with PBS and non-specific binding sites were saturated with a 10% foetal bovine serum (FBS), 0.01% Triton X100 in PBS saturation solution, incubated for 1 h at 37°C. Then, hOPC were incubated for 12 h at 4°C with mouse anti-CNPase (24 h treatments) or mouse anti-MBP (72 h treatments) primary antibodies diluted 1/250 and 1/150 respectively in the saturation solution. Then, cells were washed 3 times with PBS, and incubated with a FITC-conjugated goat anti-mouse secondary antibody (Millipore, Molsheim, France; 1/200 in saturation solution) for 1 h at 37°C. After 3 washes with PBS, the slides were mounted with Vectastain® mounting medium containing DAPI (Vector Laboratories, Burlingame, CA). Staining was visualized by fluorescent microscopy using an Axioscope microscope (Zeiss, Feldbach, Switzerland).
Myelin markers immunoreactive cells and total number of cells were counted in 10 different randomized fields per culture chamber.
Statistical analysis
Data were modelled by non-linear regression to analyse concentration-response curves and to generate Schild-plot and EC 50 or IC 50 values. Kolmogorov-Smirnov normality test was applied to all data sets. Student's t-test was used to compare each group to the control group when data passed the normality test, otherwise Mann-Whitney rank sum test was used to compare non-normal data. p values b 0.05 were considered significant. Statistical analyses were performed with SigmaStat 3.5 (Systat inc., San Jose, CA, USA), Prism 5.04 (GraphPad Software, La Jolla, CA) was used to plot the data and for calculations.
Results
Pharmacological characterisation of MSRV-Env, an agonist of recombinant human TLR4
HEK-Blue™ hTLR4 cells were designed for the monitoring of recombinant hTLR4 activation through a SEAP reporter gene. In this model LPS, the full length MSRV-Env (MSRV-Env-T), the surface domain of MSRV-Env (MSRV-Env-SU) and the glycosylated MSRV-Env-SU (MSRV-Env-SUG) induce a concentration-dependent activation of recombinant hTLR4 (Fig. 1a) . The maximal effects of LPS, MSRV-Env-T and MSRV-Env-SU (absorbance at 650 nm of 1.08 ± 0.01, 0.89 ± 0.01 and 1.07 ± 0.01 respectively) are not significantly different and maximal MSRV-Env-SUG effect was not achieved in these conditions. Submaximal concentrations of LPS and MSRV-Env-T do not stimulate the parental negative control HEK-Blue™ Null2 cells, which suggests that MSRV-Env behaves as a full agonist of recombinant hTLR4 in this model (Fig. 1a) .
LPS-induced recombinant hTLR4 activation is inhibited by anti-CD14 or anti-TLR4 antibodies and by PMB (−95%, −82% and −97% respectively) but not by corresponding isotype control antibodies (Fig. 1b) . In contrast, the recombinant hTLR4 activation by MSRV-Env-T is inhibited by an anti-CD14 antibody (− 68%) but not by its isotype control or PMB. MSRV-Env-T effect is strongly antagonized by an anti-TLR4 antibody (− 96%) and slightly but significantly by the anti-TLR4 isotype control (−13%). However, the inhibitions induced by the anti-TLR4 antibody and its isotype control are significantly different (Fig.  1c) . MSRV-Env-SU effect on the recombinant hTLR4 is inhibited by anti-CD14 or anti-TLR4 antibodies and by PMB (− 83%, − 72% and −9% respectively) but not by corresponding isotype control antibodies (Fig. 1d) . The recombinant hTLR4 activation induced by MSRV-Env-SUG is antagonized by anti-CD14 or anti-TLR4 antibodies (−81% and −66% respectively) and by PMB, though not significantly (−21%). MSRV-Env-SUG effect is not affected by corresponding isotype control antibodies (Fig. 1e) . The specific inhibition of all forms of MSRV-Env by anti-CD14 and anti-TLR4 antibodies suggests further that MSRV-Env behaves as an agonist of recombinant hTLR4 in this model.
Next, we performed a complete pharmacological profiling of MSRVEnv effects on recombinant hTLR4. LPS effect is suppressed by LPS-RS, a competitive LPS antagonist, and by Cli-095, a specific TLR4 signalling inhibitor (−100%). LPS effect is slightly though significantly inhibited by GNbAC1, a humanized monoclonal IgG4 antibody targeting MSRV-Env (− 16%). However, this small GNbAC1 effect is not specific as it is mimicked by corresponding GNbAC1 vehicle or by its isotype control (− 18% and − 33% respectively) (Fig. 2a) . In contrast to LPS, MSRVEnv-T effect is inhibited by GNbAC1 (−53%) but not by corresponding GNbAC1 vehicle or isotype control (Fig. 2b) . Similarly, MSRV-Env-SU and MSRV-Env-SUG effects are antagonized by GNbAC1 (− 33% and − 46% respectively) without being affected by GNbAC1 vehicle and isotype control ( Fig. 2c and d) . The effects of all MSRV-Env preparations are suppressed by LPS-RS and Cli-095, suggesting further that MSRV-Env is an agonist of recombinant hTLR4. GNbAC1, Cli-095 (Fig. 3a) , LPS-RS and an anti-TLR4 antibody (Fig. 3b) inhibit MSRV-Env-T in a concentration-dependent manner, with IC 50 of 5.8 ± 0.2 nM, 274 ± 1 nM, 161 ± 7 g mL −1 and 218 ± 29 g mL −1 respectively. A complete antagonism of MSRV-Env-T by GNbAC1 was not achieved in this model. The concentration-dependent activation of recombinant hTLR4 ). hTLR4 activation was monitored colorimetrically using a SEAP reporter gene placed under the control of an NF-κB inducible promoter. Data are expressed as absorbance at 650 nm (a) or as % of control response to LPS, MSRVEnv-T, MSRV-Env-SU, and MSRV-Env-SUG alone (b-e; in the absence of antagonist; OD 650 nm of 0.40 ± 0.03, 0.49 ± 0.06, 0.56 ± 0.03, and 0.52 ± 0.04 respectively) and are Means ± SEM from 6 to 12 experiments. **P b 0.01, ***P b 0.001 versus agonist alone.
by MSRV-Env-T is highly potent, with an EC 50 of 0.36 ± 0.03 nM (Fig.  3c) . MSRV-Env-T concentration-response curve is shifted rightward by increasing concentrations of LPS-RS with no decrease in the maximal effect. The slope of the corresponding Schild analysis is 0.94 ± 0.03, with a 95% confidence interval that includes 1.00 (0.79 to 1.10), demonstrating that LPS-RS is a competitive antagonist of MSRV-Env-T (Fig. 3d) .
TLR4-dependent pro-inflammatory properties of MSRV-Env are inhibited by GNbAC1 in vitro and in vivo
We then sought to investigate MSRV-Env interactions with native hTLR4 in cultured hPBMC. A 24 h stimulation with MSRV-Env-T induces a potent and concentration-dependent release of the pro-inflammatory cytokines IL-6 (EC 50 of 0.20 ± 0.11 nM, maximal release of 9866 ± 923 pg mL −1 at 3 nM; Fig. 4a ) and TNF-α (EC 50 of 1.08 ± 0.09 nM, maximal release of 409 ± 37 pg mL −1 at 3 nM; Fig. 4b ) in cultured hPBMC. The MSRV-Env-T induced release of IL-6 (Fig. 4c ) and TNF-α (Fig. 4d) is antagonized by GNbAC1 (− 69% and − 64% respectively) but not by corresponding GNbAC1 vehicle, by an anti-TLR4 (− 88% and −68% respectively) antibody but not by its corresponding isotype control, by LPS-RS (− 93% and − 95% respectively) and by Cli-095 (−72% and − 80% respectively). Similarly to observations made with recombinant hTLR4, MSRV-Env is a highly potent agonist of native hTLR4 expressed by hPBMC, is specifically inhibited by GNbAC1 in this model, which therefore confirms MSRV-Env strong pro-inflammatory properties. Studies performed with murine TLR4 (mTLR4) expressed in HEKBlue™ mTLR4 cells demonstrated that MSRV-Env-T is also a highly potent mTLR4 agonist, with an EC 50 of 0.085 ± 0.001 nM in this model (Fig. 4e) . Thus, we have investigated if MSRV-Env presents proinflammatory properties and assessed GNbAC1 putative beneficial effect in mice. MSRV-Env-T injected intravenously at 3.3 mg kg ) antagonized the release of IL-6 (+ 3365 ± 978 pg mL − 1 ; − 69%) and TNF-α (+ 176 ± 50 pg mL − 1 ; −49%) induced by MSRV-Env-T in mice (Fig. 4f) .
MSRV-Env-T induced impairment of hOPC differentiation to myelinating cells is TLR4-dependent and suppressed by GNbAC1
Then, we have investigated MSRV-Env interactions with native hTLR4 and assessed GNbAC1 potential benefit in primary cultured hOPC. We detect the expression of hTLR4 on the surface of hOPC cultured for 72 h by immunocytochemistry performed with a selective anti-TLR4 antibody (Fig. 5a) . A 24 h incubation with MSRV-Env-T induces a decrease of the proportion of hOPC expressing CNPase, the ), or Cli-095 (1 μM). Then, cells were subsequently incubated during 15.5 h with antagonists only. hTLR4 activation was monitored colorimetrically using a SEAP reporter gene placed under the control of an NF-κB inducible promoter. Data are expressed as % of control response to LPS, MSRV-Env-T, MSRV-Env-SU, and MSRV-Env-SUG alone (in the absence of antagonist; OD 650 nm of 0.24 ± 0.02, 0.17 ± 0.01, 0.34 ± 0.01, and 0.09 ± 0.01 respectively) and are Means ± SEM from 6 to 12 experiments. ***P b 0.001 versus agonist alone. earliest marker of hOPC differentiation to mature myelinating oligodendrocytes (− 24%). Similarly, a 72 h stimulation with MSRV-Env-T induces a decrease of the proportion of hOPC expressing MBP, a late marker of hOPC differentiation to myelinating cells (−35%) (Fig. 5b) .
The decrease of CNPase and MBP expressions induced by MSRVEnv-T in hOPC is antagonized by GNbAC1 (− 94% and − 100% respectively), by LPS-RS (− 100% for both myelination markers) and by Cli-095 (− 100% and − 88% respectively) (Fig. 5c ). GNbAC1 concentration-dependently, potently and fully antagonizes these hTLR4-mediated MSRV-Env-T effects on CNPase (IC 50 = 7.79 ± 0.24 nM) and MBP (IC 50 = 5.12 ± 0.14 nM) expressions (Fig. 5d) , and GNbAC1 effect is specific since it was not reproduced by corresponding GNbAC1 vehicle or by its isotype control (Fig. 5c ).
Discussion and conclusions
Pro-inflammatory properties of MSRV Envelope protein were previously reported and attributed to a TLR4 stimulation (Perron et al., 2001; Rolland et al., 2006; Saresella et al., 2009 ). Based on a functional assay of recombinant hTLR4 stimulation, the data presented here demonstrates that all available forms of recombinant MSRV-Env present an identical pharmacological profile and behave as full agonists of recombinant hTLR4. Similarly to LPS, MSRV-Env effects are antagonized by LPS-RS, a competitive LPS antagonist extracted from R. sphaeroides (Stevens et al., 2013) , by Cli-095, a selective inhibitor of TLR4 signalling (Kawamoto et al., 2008; Matsunaga et al., 2011) , and by anti-CD14 or anti-TLR4 antibodies. LPS-RS also behaves as a competitive MSRV-Env-T antagonist, showing that MSRV-Env binds TLR4 close to or in the same binding pocket as LPS. Stimulation of recombinant hTLR4 by MSRV-Env-T is concentration-dependent and highly potent, with an EC 50 in the picomolar range, which demonstrates that hTLR4 is a major MSRV-Env receptor. Syncytin-1 is a domesticated envelope protein from the HERV-W family. It is mainly expressed in human placenta during pregnancy, where it mediates syncytium formation through an interaction with the sodium-dependent neutral amino-acid transporters ASCT-1 and ASCT-2 (Cheynet et al., 2006; Lavillette et al., 2002) . MSRV-Env and Syncytin-1 transcripts only differ by an insertion of 12 nucleotides in the corresponding trans-membrane domain of the proteins, and the lack of discriminating tools has generated confusing reports in the literature (Dolei et al., 2015; Laufer et al., 2009 ). Thus, ASCT-1 and ASCT-2 transporters may also function as additional MSRV-Env receptors, apart from its potent binding to hTLR4.
Polymyxin B is a selective LPS inhibitor (Scott et al., 2000) . It does not modulate MSRV-Env-T but it inhibits approximately 20% of MSRVEnv-SU and MSRV-Env-SUG effects, which reveals trace amounts of LPS remains in these preparations. For this reason, all further studies presented here were performed with MSRV-Env-T, which is a well characterised preparation. Traces of MSRV-Env and LPS rapidly elicit a strong and irreversible stimulation of HEK-Blue ™ hTLR4 cells. We have progressively adapted the manufacturer's protocol (24 h of stimulation by agonists) to a new one suitable for antagonists' pharmacology by reducing the stimulation to 30 min followed by 15.5 h of incubation. Furthermore, we observed that trace amounts of LPS contaminants in several foetal bovine serum lots (Kirikae et al., 1997) affect this model, Fig. 3 . Concentration-dependent inhibition of MSRV-Env-T induced recombinant hTLR4 activation by GNbAC1 and selective TLR4 antagonists. HEK-blue™ hTLR4 cells were stimulated 24 h with MSRV-Env-T (3 nM) alone or together with increasing concentrations of Cli-095 (a), LPS-RS, an anti-TLR4 antibody or its isotype control (IC-TLR4; b). For GNbAC1, HEKblue™ hTLR4 cells were stimulated 30 min with MSRV-Env-T (3 nM) alone or together with increasing concentrations of GNbAC1 or its isotype control (IC-GNbAC1; a), then cells were subsequently incubated during 15.5 h with GNbAC1 only. hTLR4 activation was monitored colorimetrically using a SEAP reporter gene placed under the control of an NF-κB inducible promoter. Data are expressed as % of control response to MSRV-Env-T alone (in the absence of antagonist; OD 650 nm of 0.40 ± 0.03) and are Means ± SEM from 6 to 12 experiments. c: Increasing concentrations of LPS-RS produce increasing rightward shifts in the concentration-response curve to MSRV-Env-T. d: The Schild-plot of these responses constructed by plotting log(concentration ratio -1) by concentrations of LPS-RS. The Schild-plot slope is 0.94 ± 0.03 and is not different than 1.00, suggesting a single site competitive antagonism. Data are expressed as % of control maximal response to MSRV-Env-T (10 nM, in the absence of antagonist) and are Means ± SEM from 6 to 9 experiments. and we finally adopted the use of serum-free media dedicated to HEK293 cells or hPBMC cultures in subsequent studies.
TLR are known to detect "pathogen-associated molecular patterns" (PAMP) as LPS or viral double-stranded RNA. Recently, TLR were implicated in recognizing autologous components termed "danger-associated molecular patterns" (DAMP). DAMP encompass various molecules as HSP60 or S100A9, normally sequestered from the immune response but released or exposed by stressed or dying cells to deliver a danger signal (Hanke and Kielian, 2011; Vacchelli et al., 2013) . MSRV-Env is encoded by HERV genes belonging to the human genome and cannot be classified as a classical PAMP or DAMP, but may be considered as the first highly potent and well characterised PAMP with an endogenous origin. Although hTLR4 is generally considered as a sensor to Gram negative bacteria, it has been shown that TLR4 is sensitive to viral envelope proteins as respiratory syncytial virus (Rallabhandi et al., 2012) or mouse mammary tumour virus (Burzyn et al., 2004) . The findings of this study are in line with these previous observations. TLR4 initiates strong innate immune responses upon exposure to LPS, mirrored by subsequent production of pro-inflammatory cytokines. We performed the first pharmacological characterisation of MSRV-Env-T effects on cultured hPBMC and we show that it induces a concentration-dependent release of IL-6 and TNF-α, with affinities in ) is administered alone or together with GNbAC1 (1.6 mg kg −1 ) to mice intravenously 2 h prior blood collection, serum preparation, and cytokines dosage. Data are expressed as pg mL −1 of cytokine released above its basal level determined in control mice (3022 ± 590 pg mL −1 for IL-6 and 185 ± 23 pg mL −1 for TNF-α) and are Means ± EM from 9 to 10 mice per group. *P b 0.05, **P b 0.01, ***P b 0.001 versus MSRV-Env-T alone.
the picomolar or low nanomolar range. In this model, MSRV-Env-T is inhibited by all selective hTLR4 antagonists tested and behaves as a highly potent agonist of native hTLR4. In line with these findings, we show for the first time that MSRV-Env-T is the molecular determinant of MSRV pro-inflammatory properties in vivo as its inoculation induces a robust release of IL-6 and TNF-α in mice. Several studies suggest that MS has an autoimmune component and is associated with inflammation as TNF-α and IL-6 are up-regulated in MS patients' serum and/or CSF (Frei et al., 1991; Huang et al., 1999; Maimone et al., 1991; Polachini et al., 2014; Sharief and Hentges, 1991) . Independent reports showed that MSRV-Env expression is increased in the blood of MS patients and we demonstrate here that MSRV-Env induces a strong TLR4-dependent activation of innate immunity. These massive pro-inflammatory properties appear to be the most upstream effects of MSRV-Env which also exerts downstream superantigen-like effects (Perron et al., 2001) . The ability of superantigens to cause antigen-independent polyclonal activation of T lymphocytes can result in abnormal autoreactive T-cell activation (Zhang et al., 1995) and massive oversecretion of pro-inflammatory cytokines (Arad et al., 2000) . Superantigen properties of bacterial or viral antigens are frequently proposed as a causative factor of autoimmune diseases (Delogu et al., 2011; Sfriso et al., 2010; Wucherpfennig, 2001 ). Thus, peripheral overexpression of MSRV-Env associated with MS is clinically relevant as it may play a pivotal role by triggering inflammation and the initiation of the autoimmune component of the disease through its hTLR4 agonistic properties.
OPC are the non myelinating precursors of mature myelinating oligodendrocytes, which are crucial for nerve conduction in the CNS (Bradl and Lassmann, 2010) . Recently, it was shown that MSRV-Env decreases the expression of CNPase and MBP in rat OPC (Kremer et al., 2014 (Kremer et al., , 2013 . Here, we show that low concentrations of MSRV-Env also impair the expression of these myelination markers in human OPC through hTLR4 stimulation, which strongly suggests that it impairs hOPC differentiation to myelinating cells. Oligodendrocytes are terminally differentiated, with a limited capacity to respond to injury, and their destruction in brain lesions and disseminated demyelination are the primary morphological features of MS (Aharoni et al., 2008; Baumann and Pham-Dinh, 2001; Bruck et al., 2003; Compston and Coles, 2008) . Remyelination is mediated by OPC recruitment and differentiation. Its failure culminates in MS, in particular in its progressive forms (Aharoni et al., 2008; Baumann and Pham-Dinh, 2001; Bruck et al., 2003; Keough and Yong, 2013; Polito and Reynolds, 2005; Reynolds et al., 2002) . Immunohistochemical analyses of post mortem brain tissues from MS patients have evidenced MSRV-Env presence in MS lesions, at the vicinity of hTLR4-expressing hOPC, but not in normal appearing white matter or in control brains (Kremer et al., 2013; Perron et al., 2012). Thus, besides its involvement in inflammation, additional MSRV-Env expression in MS lesions has a strong clinical relevance as it impairs brain remyelination capacity and may play a second causative role in the aetiology of the disease.
MSRV-Env concentration-dependently promotes experimental allergic encephalomyelitis (EAE), the reference animal model of MS, in mice (Perron et al., 2013 ). The present study shows that MSRV-Env is a potent pro-inflammatory protein with deleterious properties on brain remyelination capacity, therefore confirming its potential involvement in MS physiopathology. GNbAC1, a first-in-class recombinant humanized monoclonal antibody targeting MSRV-Env, inhibits MSRVEnv induced EAE . Here, GNbAC1 concentrationdependently and specifically antagonizes the activation of recombinant hTLR4 by MSRV-Env, either produced in E. coli or in human cell line in its glycosylated form. In addition, we show that GNbAC1 specifically blocks the release of IL-6 and TNF-α induced by MSRV-Env in hPBMC in culture as well as in a corresponding murine model. This strongly suggests that GNbAC1 can inhibit the pathogenic upstream activation of the innate immune system by MSRV-Env, therefore blocking the autoimmune component as well as inflammation in MS. Furthermore, GNbAC1 fully antagonizes the decrease of CNPase and MBP expressions induced by MSRV-Env in hOPC. GNbAC1 effect is specific, concentrationdependent and highly potent, with IC 50 in the nanomolar range in this model. Thus, we propose that GNbAC1 may promote the remyelination process impaired by MSRV-Env expressed in MS lesions. Today, GNbAC1 has been studied in a phase I clinical trial in 33 healthy subjects and in a phase IIa 12 months study in 10 MS patients. GNbAC1 presents favourable linear pharmacokinetics and an excellent safety profile (Derfuss et al., 2015) .
In conclusion, MSRV-Env expression found in the blood and the brain lesions of MS patients may play a pivotal role at the crossroad of pathological hallmarks of the disease: chronic inflammation and progressive CNS demyelination associated to remyelination impairments. For the first time, we demonstrate that MSRV-Env is a highly potent and endogenous full agonist of human TLR4, which mediates its pathogenic properties. MSRV-Env is specifically antagonised by GNbAC1 in cellular and in vivo models, which strongly supports the further clinical development of GNbAC1 as a targeted causal treatment of MS, in particular in its progressive forms dominated by remyelination impairments.
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